Institut National d'Hygiene, Rabat, Maroc.
Neoplasma. 2013;60(5):553-60. doi: 10.4149/neo_2013_072.
The prognostic significance of myeloid antigen (MyAg) expression in acute lymphoblastic leukemias (ALL), especially in adult patients, is still controversial. In the present report, frequency and clinical significance of MyAg (CD13 and/or CD33) in blast cells were assessed in 80 consecutive adult (≥18 years) patients with B-lineage acute lymphoblastic leukemia (B-ALL), representing 66.7% of 120 patients diagnosed as having ALL during the study period. Immunophenotyping was used to classify leukemic cells as Bor Tlymphoblasts and to identify the aberrant expression of myeloid-associated antigens. MyAg expression was documented in 52.5% of the 80 B-ALL cases analyzed. CD13 was the most commonly antigen expressed (36.3%) followed by CD33 (28.8%). No significant associations were found between the expression of MyAg and the presence of known adverse prognostic features (eg: age>30 years, male gender, high WBC count and Philadelphia positivity). Also, we failed to observe any statistically significant difference between MyAg-positive and MyAg-negative patients in terms of achievement of complete remission and overall survival at 3 years. This study demonstrates that the presence of MyAg on lymphoblastic cells lacks prognostic value In Moroccan patients with adult B-ALL.
髓系抗原（MyAg）在急性淋巴细胞白血病（ALL）中的表达，尤其是在成人患者中的预后意义仍存在争议。本报告评估了 80 例连续的成人（≥18 岁）B 细胞系急性淋巴细胞白血病（B-ALL）患者的原始细胞中 MyAg（CD13 和/或 CD33）的频率和临床意义，占研究期间诊断为 ALL 的 120 例患者的 66.7%。免疫表型用于将白血病细胞分类为 Bor T 淋巴细胞，并鉴定髓系相关抗原的异常表达。分析的 80 例 B-ALL 病例中有 52.5%表达了 MyAg。CD13 是最常见表达的抗原（36.3%），其次是 CD33（28.8%）。MyAg 的表达与已知的不良预后特征（例如：年龄>30 岁、男性、高白细胞计数和费城阳性）之间未发现显著关联。此外，我们未能观察到 MyAg 阳性和 MyAg 阴性患者在 3 年完全缓解和总生存方面的任何统计学显著差异。这项研究表明，在摩洛哥成人 B-ALL 患者中，淋系细胞上的 MyAg 缺乏预后价值。
